國家衛健委:內地爭年底前完成3至11歲人羣完成接種新冠疫苗
國家衛健委公佈,根據國務院聯防聯控機制安排,按照知情同意自願的原則,全國積極引導3至11歲適齡無禁忌人羣「應接盡接」,力爭12月底前完成全程接種。
內地目前批準3至17歲人羣緊急使用的疫苗僅有滅活疫苗這條技術路線,需接種兩劑次,間隔三至八週。
內地3至11歲兒童接種新冠疫苗後,如需再接種其他的免疫規劃疫苗或者非免疫規劃疫苗,需間隔14天以上;如已經接種了其他的免疫規劃疫苗或者非免疫規劃疫苗,則需要間隔14天以上再接種新冠疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.